

Description

BIO⁴ is a minimally manipulated viable bone matrix processed from human cadaveric bone to retain endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells and osteoblasts, as well as osteoinductive and angiogenic growth factors.²³ The innovative principle behind BIO⁴ is to provide the next generation viable bone matrix that retains not only osteoconductive, osteoinductive and osteogenic properties of bone, but also preserves the endogenous signals (growth factors) for supporting angiogenesis. It is an alternative to autograft that minimizes the potential for harvest site comorbidities. BIO⁴ was developed by Osiris Therapeutics, Inc.

Product features²³

- A viable bone matrix that has been uniquely processed to retain the cancellous bone (scaffold and cells), cortical bone (signals) and periosteum (signals).^{23,24,25}
- Lot tested for the presence of VEGF (vascular endothelial growth factor)
- Ready to use out of the package; no decanting is required and thaws in 15 minutes
- Differentiated handling compared to the competition
- Lot tested for $\geq 600,000$ viable cells per cc post-thaw
- Lot tested for $\geq 70\%$ cell viability post-thaw
- Validated for up to a 6-hour window of post-thaw viability
- Non-immunogenic²³
- Lot tested for Bioburden and Sterility per USP 71.

BIO⁴ is processed utilizing proprietary methods. Each BIO⁴ lot is processed from a qualified single donor who undergoes extensive testing and full review of medical records by the tissue bank medical director.

BIO⁴

Reference number	Description
PS51001	1cc
PS51002	2.5cc
PS51005	5cc
PS51010	10cc



BIO⁴